Staar Surgical sees FY23 revenue $322.5M , consensus $320.5M

Operating margin is expected to be approximately 5% for the fourth quarter and fiscal 2023. “Our sales outlook for fiscal 2024 balances the recent industry trends and challenging economic environment for consumers against our conviction that ICL will continue to capture refractive market share globally. We therefore expect our net sales for fiscal 2024 will be approximately $335 million to $340 million which contemplates above-industry rates of growth of approximately 10% for ICL sales in both China and the U.S.3 We will continue to be disciplined in our investments on the path to realizing our market opportunity and anticipate our GAAP operating margin and earnings will be at least breakeven for fiscal 2024. We are confident our actions will increasingly resonate with a growing number of surgeons and patients in both large and emerging markets globally,” concluded Mr. Frinzi. Cash, cash equivalents and investments available for sale was approximately $230 million as of December 29 an increase of approximately $28 million from $201.7 M at September 29 . Accounts receivable was approximately $90M as of December 29..